Sorafenib is an orally active multikinase inhibitor with a well-documented activity in advanced RCC. Several clinical trials confirmed the efficacy of Sorafenib in different subgroups of patients with metastatic disease. Overall more than 80% of the patients affected by RCC can achieve disease control with this targeted agent. The most important evidence in terms of tumor shrinkage and disease control was reported in patients who failed a previous cytokines-based regimen or were unsuitable for such therapy. A subsequent study confirmed the efficacy results also in unselected populations including non-clear cells histotypes, brain metastases, elderly and untreated patients. The safety profile of Sorafenib has been extensively documented in more than four thousand patients. The grade of side effects is usually mild or moderate and always reversible and manageable. The safety data reported in patients with cardiac, renal or hepatic impairment are also encouraging Currently, Sorafenib could be considered as the reference treatment for elderly or frail patients independently on the histotypes; besides this agent is an adequate therapy for patients who failed to a cytokines or an anti-angiogenetic therapy such as Sunitinib or Bevacizumab.
|Number of pages||6|
|Journal||Geriatric and Medical Intelligence|
|Publication status||Published - 2009|
ASJC Scopus subject areas
- Geriatrics and Gerontology